| Trial | Treatments | Patients | Method |
|---|
| Bakris, 2002 | orlistat (n=278) vs. placebo (n=276) | obese individuals with inadequately controlled hypertension.
| double-blind Sample size: 278/276 Primary endpoint: FU duration: 1-year |
| Broom, 2002 | orlistat (n=265) vs. placebo (n=261) | obese patients with cardiovascular risk | double-blind parallel group Sample size: 265/261 Primary endpoint: FU duration: 54-week |
| Broom,, 2001 | (n=71) vs. (n=71) | | Sample size: 71/71 Primary endpoint: FU duration: |
| Davidson, 1999 | orlistat, 120 mg 3 times a day, for 52 weeks (n=668) vs. placebo (n=224) | Obese adults (BMI 30-43 kg/m2) | double-blind Sample size: 668/224 Primary endpoint: FU duration: 52 weeks |
| Deerochanawong,, 2001 | (n=126) vs. (n=126) | | Sample size: 126/126 Primary endpoint: FU duration: |
| Derosa, 2003 | orlistat 120 mg TID (n=27) vs. placebo (n=23) | obese patients with hypercholesterolemia | double-blind Sample size: 27/23 Primary endpoint: FU duration: 1-year |
| Gotfredsen, 2001 | (n=16) vs. (n=14) sous groupe | | Sample size: 16/14 Primary endpoint: FU duration: |
| Halpern, 2003 | orlistat (120 mg t.i.d.), (n=169) vs. placebo (n=174) | Obese, non-insulin-dependent diabetic patients, aged 18-70 years old, with BMI > 27 kg/m2 | Double-blind parallel Sample size: 169/174 Primary endpoint: FU duration: 24 weeks |
| Hanefeld, 2002 | orlistat 120 mg t.i.d. (n=195) vs. placebo (n=188) | Overweight or obese adults (BMI >or= 28 kg/m2) with HbA1c of 6.5-11% and clinical type 2 diabetes | double-blind Sample size: 195/188 Primary endpoint: FU duration: 48-week |
| Hauptman, 2000 | 60 mg of orlistat TID or 120 mg of orlistat TID, (n=210) vs. placebo (n=212) | obese patients (BMI 30-44 kg/m2) | double-blind Sample size: 210/212 Primary endpoint: FU duration: 1 year |
| Hill, 1999 | 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y (n=181) vs. placebo (n=188) | Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy | double-blind Sample size: 181/188 Primary endpoint: FU duration: 1 year |
| Hollander, 1998 | 120 mg orlistat orally three times a day (n=163) vs. placebo (n=159) | obese men and women with type 2 diabetes who were aged > 18 years, had a BMI of 28-40 kg/m2, and were clinically stable on oral sulfonylureas | double-blind Sample size: 163/159 Primary endpoint: FU duration: 57-week |
| Karhunen, 2000 | orlistat 120 mg t.i.d.
(n=36) vs. placebo (n=36) | obese subjects | double-blind Sample size: 36/36 Primary endpoint: FU duration: 1 y. |
| Kelley, 2002 | orlistat 120 mg three times a day (n=274) vs. placebo (n=276) | overweight or obese adults (BMI 28-40 kg/m(2)) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA(1c) 7.5-12.0%) | double-blind Sample size: 274/276 Primary endpoint: FU duration: 1-year |
| Krempf, 2005 | orlistat 120 mg three times daily (n=346) vs. placebo (n=350) | otherwise healthy, overweight patients aged 18-65 y (BMI >or=28 kg/m2 | double-blind Sample size: 346/350 Primary endpoint: FU duration: 18-month |
| Lindgarde, 2000 | orlistat 120 mg three times daily (n=190) vs. placebo (n=186) | obese adults (body mass index 28-38 kg m-2) with type 2 diabetes, hypercholesterolaemia and/or hypertension | double-blind Sample size: 190/186 Primary endpoint: FU duration: 1 year |
| Lucas, 2003 | (n=256) vs. (n=188) | | Sample size: 256/188 Primary endpoint: FU duration: |
| Micic, 1999 | orlistat 120 mg three times daily (n=60) vs. placebo (n=59) | obese patients (BMI > or = 30 kg/m2) with hyperlipidemia (LDL-cholesterol > or = 4, 2 mmol/l) | double-blind Sample size: 60/59 Primary endpoint: FU duration: 24 weeks |
| Miles, 2002 | 120 mg orlistat t.i.d. (n=255) vs. placebo (n=261) | overweight and obese patients with suboptimal control of type 2 diabetes | double-blind Sample size: 255/261 Primary endpoint: FU duration: 1 year |
| Muls, 2001 | orlistat 120 mg three times daily (n=147) vs. placebo (n=147) | obese hypercholesterolemic patients, BMI between 27-40 kg/m2 and low-density-lipoprotein cholesterol, LDL-C, between 4.1-6.7 mmol/l | double-blind Sample size: 147/147 Primary endpoint: FU duration: 24 week |
| Naumov, 2002 | orlistat (n=15) vs. diet alone (n=15) | patients with stable angina pectoris concomitant with obesity and hyperlipemia | open Sample size: 15/15 Primary endpoint: FU duration: |
| Reaven, 2001 | (n=156) vs. (n=91) | | Sample size: 156/91 Primary endpoint: FU duration: |
| Rissanen, 2001 | orlistat 120 mg three times daily (n=25) vs. placebo (n=26) | healthy obese women | double-blind Sample size: 25/26 Primary endpoint: FU duration: 12-month |
| Rosenfalck, 2002 | (n=3) vs. (n=1) | obese patients | Sample size: 3/1 Primary endpoint: FU duration: |
| Rossner, 2000 | orlistat (60 or 120 mg) three times a day (n=244) vs. Obese patients (body mass index 28 to 43 kg/m2) (n=243) | Obese patients (body mass index 28 to 43 kg/m2) | double-blind Sample size: 244/243 Primary endpoint: FU duration: 2-year |
| Shi Yi, 2001 | (n=986) vs. (n=142) | | Sample size: 986/142 Primary endpoint: FU duration: |
| Sjostrom, 1998 | orlistat 120 mg (three times a day) (n=345) vs. (n=343) | | double-blind Sample size: 345/343 Primary endpoint: FU duration: 1 year |
| Vidgren, 1999 | 120 mg of orlistat three times a day (n=37) vs. placebo (n=38) | obese subjects | Sample size: 37/38 Primary endpoint: FU duration: 1 year |
